Eliem Therapeutics, Inc. (ELYM): Price and Financial Metrics
GET POWR RATINGS... FREE!
ELYM Stock Price Chart Interactive Chart >
ELYM Price/Volume Stats
| Current price | $3.85 | 52-week high | $11.51 |
| Prev. close | $3.62 | 52-week low | $2.36 |
| Day low | $3.64 | Volume | 1,200 |
| Day high | $3.85 | Avg. volume | 18,500 |
| 50-day MA | $3.17 | Dividend yield | N/A |
| 200-day MA | $3.59 | Market Cap | 102.29M |
Eliem Therapeutics, Inc. (ELYM) Company Bio
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems in the United States. The company's lead clinical-stage candidates include ETX-810, a novel palmitoylethanolamide prodrug that is in Phase IIa clinical trials for the treatment of diabetic peripheral neuropathic pain and pain associated with lumbosacral radiculopathy; and ETX-155 is a neurosteroid GABAA receptor positive allosteric modulator for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures. Its lead preclinical program includes Kv7.2/3 potassium channel opener for epilepsy and pain; and novel analog of 2,3- benzodiazepine for the treatment of generalized anxiety disorder. The company was incorporated in 2018 and is headquartered in Redmond, Washington.
Latest ELYM News From Around the Web
Below are the latest news stories about ELIEM THERAPEUTICS INC that investors may wish to consider to help them evaluate ELYM as an investment opportunity.
Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual ConferenceSEATTLE and CAMBRIDGE, United Kingdom, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today announced that Bob Azelby, Eliem’s president and chief executive officer, will present at the 5th Annual Evercore ISI HealthCONx Virtual Conference being held virtually on Thursday, December 1, 2022 at 11:40 AM ET. |
Eliem Theraputics (NASDAQ:ELYM)The following slide deck was published by Eliem Therapeutics, Inc. |
Eliem Therapeutics GAAP EPS of -$0.37 beats by $0.06 (NASDAQ:ELYM)Eliem Therapeutics press release (ELYM): Q3 GAAP EPS of -$0.37 beats by $0.06.Cash, cash equivalents and short- and long-term marketable securities was $129.6 million as of September… |
Eliem Therapeutics Reports Third Quarter Financial and Business HighlightsPositioned to initiate ETX-155 Phase 2a trial in major depressive disorder in the first quarter of 2023 with 60-milligram dose Progressing IND-enabling studies for two Kv7 pre-candidates with safety studies planned in the first quarter of 2023 Cash runway expected to fund operations into 2025 SEATTLE and CAMBRIDGE, United Kingdom, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal ex |
Is Eliem Therapeutics (NASDAQ:ELYM) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
ELYM Price Returns
| 1-mo | 19.94% |
| 3-mo | 15.96% |
| 6-mo | 26.64% |
| 1-year | -54.55% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 4.90% |
| 2022 | -64.91% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...